Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. UroGen Pharma's Revenue for the
three
months ended in Mar. 2026 was $51.0 Mil. UroGen Pharma's average Accounts Receivable for the
three
months ended in Mar. 2026 was $44.2 Mil.
Hence, UroGen Pharma's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.15.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
UroGen Pharma Receivables Turnover Related Terms
UroGen Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for UroGen Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0XOD vs PVLA, AUPH, RAPP: Receivables Turnover Comparison
For the Biotechnology subindustry, UroGen Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UroGen Pharma (LTS:0XOD) has a Receivables Turnover of 1.15 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on UroGen Pharma and its competitors. According to the industry distribution chart, UroGen Pharma ranks #461 out of 841 companies in the Biotechnology industry, placing it in the top 54.8%.
Is UroGen Pharma's Receivables Turnover too high?
UroGen Pharma's current Receivables Turnover is 1.15. The Biotechnology industry median Receivables Turnover is 5.28. UroGen Pharma's value of 1.15 is 78.2% below this industry median. Based on the distribution chart, UroGen Pharma ranks #461 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, UroGen Pharma has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's Receivables Turnover compare to PVLA and AUPH?
According to the Biotechnology industry distribution chart, UroGen Pharma ranks #461 out of 841 companies for Receivables Turnover. This places UroGen Pharma in the lower half of its industry. The industry median Receivables Turnover is 5.28. UroGen Pharma's value of 1.15 is 78.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UroGen Pharma's current Receivables Turnover of 1.15 is 78.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on UroGen Pharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UroGen Pharma's current Receivables Turnover is 1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (LTS:0XOD) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.35, compared to a current price of $38.54 — trading 72.4% above its estimated fair value. The current Receivables Turnover is 1.15 and 78.2% below the Biotechnology industry median of 5.28. UroGen Pharma's overall GF Score™ is 52/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For UroGen Pharma (LTS:0XOD), the current Receivables Turnover is 1.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UroGen Pharma (LTS:0XOD) Overvalued in 2026?
Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued.
The current stock price of $38.54 is trading 72.4% above its estimated GF Value™ of $22.35.
GuruFocus considers UroGen Pharma to be Significantly Overvalued.
Key valuation signals for LTS:0XOD:
Receivables Turnover: 1.15
GF Value™: $22.35 vs. price of $38.54 (72.4% above fair value)
Industry Position: 78.2% below the Biotechnology median (#461 of 841)
No single metric tells the full story. See the LTS:0XOD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
52GF Score
Get the complete analysis for LTS:0XOD
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0XOD has been successfully added to your 
